138 related articles for article (PubMed ID: 3412323)
1. The non-human primate: a possible model for human genetically determined polymorphisms in oxidative drug metabolism.
Jacqz E; Billante C; Moysan F; Mathieu H
Mol Pharmacol; 1988 Aug; 34(2):215-7. PubMed ID: 3412323
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
Saner H; Gurtner HP; Preisig R; Küpfer A
Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
[TBL] [Abstract][Full Text] [Related]
3. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
[TBL] [Abstract][Full Text] [Related]
4. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
Atiba JO; Blaschke TF; Wilkinson GR
Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
[TBL] [Abstract][Full Text] [Related]
8. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
Spina E; Buemi AL; Sanz E; Bertilsson L
Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacogenetics of oxidation reactions of drugs].
Jacqz-Aigrain E
Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
[TBL] [Abstract][Full Text] [Related]
11. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.
Xie HG; Xu ZH; Luo X; Huang SL; Zeng FD; Zhou HH
Pharmacogenetics; 1996 Jun; 6(3):235-8. PubMed ID: 8807662
[TBL] [Abstract][Full Text] [Related]
13. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
14. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Sanz EJ; Bertilsson L
Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
[TBL] [Abstract][Full Text] [Related]
15. [Individual difference in drug metabolism--pharmacogenetical approach].
Nemoto N
Gan To Kagaku Ryoho; 1982 May; 9(5):757-65. PubMed ID: 6764111
[TBL] [Abstract][Full Text] [Related]
16. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alván G; Bechtel P; Iselius L; Gundert-Remy U
Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
[TBL] [Abstract][Full Text] [Related]
17. [Heritable polymorphisms in oxidative drug metabolism].
Kallio J
Duodecim; 1990; 106(5):408-14. PubMed ID: 1670108
[No Abstract] [Full Text] [Related]
18. [Knowledge about metabolic capacity is important in drug therapy].
Alván G; Dahl ML
Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic drug metabolism.
Relling MV
Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Dayer P; Courvoisier F; Kupfer A; Balant-Gorgia A; Balant L; Fabre J
Schweiz Med Wochenschr; 1983 Feb; 113(8):295-7. PubMed ID: 6133350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
